相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study
Yasmin Ben-Dali et al.
LEUKEMIA & LYMPHOMA (2020)
A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.
Matthew Steven Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)
Pau Abrisqueta et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Pembrolizumab in relapsed or refractory Richter syndrome
Philippe Armand et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
Lenka Sedlarikova et al.
FRONTIERS IN ONCOLOGY (2020)
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome
Andrea Visentin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
PD-1 is highly expressed by neoplastic B-cells in Richter transformation
Amir Behdad et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome
Juan Pablo Alderuccio et al.
LEUKEMIA & LYMPHOMA (2019)
Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia
Richard Kiss et al.
HAEMATOLOGICA (2019)
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
Ian W. Flinn et al.
BLOOD (2019)
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
John C. Byrd et al.
BLOOD (2019)
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis
Toby A. Eyre et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Relevance of TP53 for CLL diagnostics
Mark A. Catherwood et al.
JOURNAL OF CLINICAL PATHOLOGY (2019)
Risk factors associated with Richter's transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population-based cohort study
Mariam Hussein Hleuhel et al.
BMJ OPEN (2019)
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Andrew W. Roberts et al.
BLOOD (2019)
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Lindsey E. Roeker et al.
CLINICAL CANCER RESEARCH (2019)
Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome
C. P. Reinert et al.
EUROPEAN RADIOLOGY (2019)
A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II TRIAL EVALUATING SAFETY AND EFFICACY OF VENETOCLAX, ATEZOLIZUMAB ANDOBINUTUZUMAB IN RICHTER TRANSFORMATION FROM CLL
M. Montillo et al.
HEMATOLOGICAL ONCOLOGY (2019)
PHASE I/II STUDY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB (TG-1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION
A.R. Mato et al.
HEMATOLOGICAL ONCOLOGY (2019)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Jeff P. Sharman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece
Maria Dimou et al.
LEUKEMIA & LYMPHOMA (2019)
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
Richard Lemal et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics
Anna Petrackova et al.
FRONTIERS IN ONCOLOGY (2019)
Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Krish Patel et al.
BLOOD (2019)
A CRISPR/Cas9-Generated Murine Model Reveals Cooperation between BCR Signaling and CDKN2A/2B and TP53 Disruption in Richter Syndrome
Supriya Chakraborty et al.
BLOOD (2019)
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
Jan A. Burger et al.
BLOOD (2019)
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation
Rashmi Kanagal-Shamanna et al.
CANCER (2019)
The involvement of microRNA in the pathogenesis of Richter syndrome
Katrien Van Roosbroeck et al.
HAEMATOLOGICA (2019)
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
Maria Winqvist et al.
HAEMATOLOGICA (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
G. Fraser et al.
LEUKEMIA (2019)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
Susan M. O'Brien et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Farrukh T. Awan et al.
BLOOD ADVANCES (2019)
Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis
Elisabeth Nuttall et al.
JOURNAL OF BLOOD MEDICINE (2019)
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT) A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness
Rong He et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales
Birgit Federmann et al.
ANNALS OF HEMATOLOGY (2018)
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
Steven Coutre et al.
BLOOD (2018)
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Inhye E. Ahn et al.
BLOOD (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MYD88 Mutations and Sensitivity to Ibrutinib Therapy
Y. Lynn Wang
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Jeffrey A. Jones et al.
LANCET ONCOLOGY (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
Benjamin L. Lampson et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Carmen D. Herling et al.
NATURE COMMUNICATIONS (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
Xiaojun Huang et al.
CANCER MEDICINE (2018)
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia
Emanuela Rosati et al.
FRONTIERS IN ONCOLOGY (2018)
miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients
Veronica Balatti et al.
BLOOD (2018)
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
Paula Cramer et al.
LANCET ONCOLOGY (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
Kerry A. Rogers et al.
BLOOD (2018)
Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL
Jordan Gauthier et al.
BLOOD (2018)
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor
Kerry A. Rogers et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies
Maliha Khan et al.
ANNALS OF HEMATOLOGY (2018)
Richter transformation in the era of novel agents
Wei Ding
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)
The 2016 updated WHO classification of lymphoid neoplasias
Leticia Quintanilla-Martinez
HEMATOLOGICAL ONCOLOGY (2017)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Andrew D. Zelenetz et al.
LANCET ONCOLOGY (2017)
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
John F. Seymour et al.
LANCET ONCOLOGY (2017)
Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia
Giulia Fabbri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia
Paul Yeh et al.
NATURE COMMUNICATIONS (2017)
Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy.
Matthew Steven Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Richter's Syndrome with Hypercalcemia Induced by Tumor-Associated Production of Parathyroid Hormone-Related Peptide
Naoki Watanabe et al.
CASE REPORTS IN ONCOLOGY (2017)
High-throughput sequencing for noninvasive disease detection in hematologic malignancies
Florian Scherer et al.
BLOOD (2017)
An update for Richter syndrome - new directions and developments
Toby A. Eyre et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Wei Ding et al.
BLOOD (2017)
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
Mary Ann Anderson et al.
BLOOD (2017)
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
John Kuruvilla et al.
BLOOD (2017)
Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib
Preetesh Jain et al.
CANCER (2017)
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL
Sabah Kadri et al.
BLOOD ADVANCES (2017)
Diffuse large B-cell lymphoma genotyping on the liquid biopsy
Davide Rossi et al.
BLOOD (2017)
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD (2017)
Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
Rose Lou Marie C. Agbay et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
Toby A. Eyre et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review
Elizabeth J. Soilleux et al.
HISTOPATHOLOGY (2016)
Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-Like lesion
Wenbin Xiao et al.
HUMAN PATHOLOGY (2016)
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Susan O'Brien et al.
LANCET ONCOLOGY (2016)
An 18F-FDG-PET maximum standardized uptake value>10 represents a novel valid marker for discerning Richter's Syndrome
Anne-Sophie Michallet et al.
LEUKEMIA & LYMPHOMA (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Richter syndrome: pathogenesis and management
Davide Rossi et al.
SEMINARS IN ONCOLOGY (2016)
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
Jan A. Burger et al.
NATURE COMMUNICATIONS (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
The molecular pathogenesis of chronic lymphocytic leukaemia
Giulia Fabbri et al.
NATURE REVIEWS CANCER (2016)
Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study
Peter Hillmen et al.
BLOOD (2016)
Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial
Nitin Jain et al.
BLOOD (2016)
B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia
Zaher Chakhachiro et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma
Sameer A. Parikh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2015)
The efficacy of ibrutinib in the treatment of Richter syndrome
Mazie Tsang et al.
BLOOD (2015)
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain et al.
BLOOD (2015)
Second Cancers and Richter Transformation Are the Leading Causes of Death in Patients With Trisomy 12 Chronic Lymphocytic Leukemia
Paolo Strati et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study
Eric Durot et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
The pathology of transformation of indolent B cell lymphomas
Randy D. Gascoyne
HEMATOLOGICAL ONCOLOGY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease
F. R. Mauro et al.
LEUKEMIA (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation
Petra Langerbeins et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia
Lorenzo Falchi et al.
BLOOD (2014)
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2014)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Susan O'Brien et al.
LANCET ONCOLOGY (2014)
2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation
Tomas Papajik et al.
LEUKEMIA & LYMPHOMA (2014)
Risk Factors for Richter Syndrome in Chronic Lymphocytic Leukemia
Sameer A. Parikh et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Ekaterina Chigrinova et al.
BLOOD (2013)
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Conrad Russell Y. Cruz et al.
BLOOD (2013)
Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients
Sameer A. Parikh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Apostolia M. Tsimberidou et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
Giulia Fabbri et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia
Lorenzo De Paoli et al.
LEUKEMIA & LYMPHOMA (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
NOTCH1 mutations in CLL associated with trisomy 12
Veronica Balatti et al.
BLOOD (2012)
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations
Jennifer Edelmann et al.
BLOOD (2012)
Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature
Bruno Bockorny et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome
Davide Rossi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
NOTCH1 mutations in+12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of+12 CLL
Ilaria Del Giudice et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Molecular pathogenesis of chronic lymphocytic leukemia
Gianluca Gaidano et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Kate Cwynarski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays
M. Ciccone et al.
LEUKEMIA (2012)
Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia
Lei Fan et al.
LEUKEMIA & LYMPHOMA (2012)
The Notch signalling system: recent insights into the complexity of a conserved pathway
K. G. Guruharsha et al.
NATURE REVIEWS GENETICS (2012)
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
Davide Rossi et al.
BLOOD (2011)
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome
Silvia Rasi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases
Haipeng Shao et al.
MODERN PATHOLOGY (2011)
被撤回的出版物: Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (accelerated chronic lymphocytic leukemia) with aggressive clinical behavior (Retracted Article. See vol 95, pg 1620, 2010)
Eva Gine et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to Interdigitating Dendritic Cell Sarcoma
Cory R. Fraser et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation
Mauro Di Ianni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
Raphael Kopan et al.
CELL (2009)
Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
Davide Rossi et al.
CLINICAL CANCER RESEARCH (2009)
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia
D. Rossi et al.
LEUKEMIA (2009)
Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome
Davide Rossi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
Apostolia M. Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
IgVH mutational status and clonality analysis of Richter's transformation -: Diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution
Zhengrong Mao et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
Myc goes global: New tricks for an old oncogene
Paul S. Knoepfler
CANCER RESEARCH (2007)
Hodgkin transformation of chronic lymphocytic leukemia - The M.D. Anderson Cancer Centre Experience
Apostolia-Maria Tsimberidou et al.
CANCER (2006)
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation
Apostolia-Maria Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine
D Fong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated with EBV infection
L de Leval et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia
AM Tsimberidou et al.
CANCER (2003)
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome
BS Dabaja et al.
LEUKEMIA & LYMPHOMA (2001)
分享论文
